Page 1 | Search Results | Blood Advances | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Blood Adv bloodadvances.2024014975.

https://doi.org/10.1182/bloodadvances.2024014975

Published: 2025

Includes: Supplemental data

Journal Articles

Point-of-care CAR T manufacturing solutions: can 1 model fit all?

Álvaro Urbano-Ispizua, Nirav N. Shah, Natasha Kekre

Blood Adv (2024) 8 (23): 6133–6136.

https://doi.org/10.1182/bloodadvances.2024012982

Published: 2024

Journal Articles

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention

Fateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, Timothy S. Fenske, Faiqa Farrukh, Walter Longo, Othman Akhtar, Anita D’Souza, Marcelo Pasquini, Guru Subramanian Guru Murthy, Lyndsey Runaas, Sameem Abedin, Meera Mohan, Nirav N. Shah, Mehdi Hamadani

Blood Adv (2024) 8 (16): 4320–4329.

https://doi.org/10.1182/bloodadvances.2024013239

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

Blood Adv (2024) 8 (10): 2592–2599.

https://doi.org/10.1182/bloodadvances.2023011996

Published: 2024

Journal Articles

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Blood Adv (2024) 8 (10): 2327–2331.

https://doi.org/10.1182/bloodadvances.2024012573

Published: 2024

Journal Articles

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen

Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S. Fenske, Nirav N. Shah, Deepa Jagadeesh, Andreas Klein, Irene Helenowski, Ruohui Chen, Xinlei Mi, Adam Petrich, Andrew M. Evens, Barbara Pro

Blood Adv (2024) 8 (7): 1612–1620.

https://doi.org/10.1182/bloodadvances.2023011369

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Blood Adv (2023) 7 (21): 6630–6638.

https://doi.org/10.1182/bloodadvances.2023010622

Published: 2023

Includes: Supplemental data

Journal Articles

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Blood Adv (2023) 7 (12): 2657–2669.

https://doi.org/10.1182/bloodadvances.2022008240

Published: 2023

Includes: Supplemental data

Journal Articles

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

Fateeha Furqan, Morgan Maring, Aniko Szabo, Timothy S. Fenske, Mehdi Hamadani, Nirav N. Shah

Blood Adv (2023) 7 (11): 2463–2467.

https://doi.org/10.1182/bloodadvances.2022009025

Published: 2023

Includes: Supplemental data

Journal Articles

CAR T-cell therapy for secondary CNS DLBCL

Gulrayz Ahmed, Mehdi Hamadani, Nirav N. Shah

Blood Adv (2021) 5 (24): 5626–5630.

https://doi.org/10.1182/bloodadvances.2021005292

Published: 2021

Includes: Supplemental data

Journal Articles

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Zheng Zhou, Rajneesh Nath, Jan Cerny, Hai-Lin Wang, Mei-Jie Zhang, Hisham Abdel-Azim, Vaibhav Agrawal, Gulrayz Ahmed, A. Samer Al-Homsi, Mahmoud Aljurf, Hassan B. Alkhateeb, Amer Assal, Ulrike Bacher, Ashish Bajel, Qaiser Bashir, Minocher Battiwalla, Vijaya Raj Bhatt, Michael Byrne, Jean-Yves Cahn, Mitchell Cairo, Hannah Choe, Edward Copelan, Corey Cutler, Moussab B. Damlaj, Zachariah DeFilipp, Marcos De Lima, Miguel Angel Diaz, Nosha Farhadfar, James Foran, César O. Freytes, Aaron T. Gerds, Usama Gergis, Michael R. Grunwald, Zartash Gul, Mehdi Hamadani, Shahrukh Hashmi, Mark Hertzberg, Gerhard C. Hildebrandt, Nasheed Hossain, Yoshihiro Inamoto, Luis Isola, Tania Jain, Rammurti T. Kamble, Muhammad Waqas Khan, Mohamed A. Kharfan-Dabaja, Partow Kebriaei, Natasha Kekre, Nandita Khera, Hillard M. Lazarus, Jane L. Liesveld, Mark Litzow, Hongtao Liu, David I. Marks, Rodrigo Martino, Vikram Mathews, Asmita Mishra, Hemant S. Murthy, Arnon Nagler, Ryotaro Nakamura, Sunita Nathan, Taiga Nishihori, Rebecca Olin, Richard F. Olsson, Neil Palmisiano, Sagar S. Patel, Mrinal M. Patnaik, Attaphol Pawarode, Miguel-Angel Perales, Ioannis Politikos, Uday Popat, David Rizzieri, Brenda M. Sandmaier, Bipin N. Savani, Sachiko Seo, Nirav N. Shah, Geoffrey L. Uy, David Valcárcel, Leo F. Verdonck, Edmund K. Waller, Youjin Wang, Daniel Weisdorf, Baldeep Wirk, Eric Wong, Jean A. Yared, Wael Saber

Blood Adv (2020) 4 (13): 3180–3190.

https://doi.org/10.1182/bloodadvances.2019001266

Published: 2020

Includes: Supplemental data

Journal Articles

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome

Nirav N. Shah, Bryon D. Johnson, Timothy S. Fenske, Renju V. Raj, Parameswaran Hari

Blood Adv (2020) 4 (10): 2119–2122.

https://doi.org/10.1182/bloodadvances.2020001626

Published: 2020

Journal Articles

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT

Talha Badar, Narendranath Epperla, Aniko Szabo, Steven Borson, John Vaughn, Gemlyn George, Neeraj Saini, Abdul Rashid Shah, Romil D. Patel, Sairah Ahmed, Nirav N. Shah, Amanda F. Cashen, Mehdi Hamadani, Timothy S. Fenske

Blood Adv (2020) 4 (1): 47–54.

https://doi.org/10.1182/bloodadvances.2019000736

Published: 2020

Journal Articles

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Yi-Bin Chen, Nirav N. Shah, Anne S. Renteria, Corey Cutler, Johan Jansson, Mona Akbari, Chunlin Chen, Syed Quadri, Andrejus Parfionovas, Steven M. Devine

Blood Adv (2019) 3 (23): 4136–4146.

https://doi.org/10.1182/bloodadvances.2019000893

Published: 2019

Includes: Supplemental data

Journal Articles

Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Blood Adv (2019) 3 (19): 2836–2844.

https://doi.org/10.1182/bloodadvances.2019000627

Published: 2019

Journal Articles

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation

Narendranath Epperla, Talha Badar, Aniko Szabo, John Vaughn, Steve Borson, Neeraj Y. Saini, Romil D. Patel, Nirav N. Shah, Mehdi Hamadani, Sairah Ahmed, Amanda F. Cashen, Timothy S. Fenske

Blood Adv (2019) 3 (11): 1661–1669.

https://doi.org/10.1182/bloodadvances.2019000102

Published: 2019

Includes: Supplemental data

Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Blood Adv (2019) 3 (10): 1568–1573.

https://doi.org/10.1182/bloodadvances.2019000180

Published: 2019

Journal Articles

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Blood Adv (2018) 2 (21): 2922–2936.

https://doi.org/10.1182/bloodadvances.2018024844

Published: 2018

Includes: Supplemental data

Journal Articles

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Blood Adv (2018) 2 (8): 933–940.

https://doi.org/10.1182/bloodadvances.2018018531

Published: 2018

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Point-of-care CAR T manufacturing solutions: can 1 model fit all?

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

CAR T-cell therapy for secondary CNS DLBCL

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only